Activities of Nicola CAPUTO related to 2016/0261(COD)
Plenary speeches (1)
Criminal acts and penalties in the field of illicit drug trafficking - Information exchange on, and an early warning system and risk assessment procedure for, new psychoactive substances I (debate) IT
Amendments (4)
Amendment 24 #
Proposal for a regulation
Recital 1 a (new)
Recital 1 a (new)
(1a) New psychoactive substances, which may have numerous commercial and industrial uses, as well as scientific uses, can pose health, social and safety risks when consumed by humans.
Amendment 28 #
Proposal for a regulation
Recital 2
Recital 2
(2) During the past years, Member States have notified an increasing number of new psychoactive substances via the mechanism for rapid exchange of information which was established by Joint Action 97/396/JHA adopted by the Council on the basis of Article K.3 of the Treaty on European Union concerning the information exchange, risk assessment and the control of new synthetic drugs13 and was further strengthened by Council Decision 2005/387/JHA14. A large majority of these new psychoactive substances were reported by more than one Member State. Many such new psychoactive substances were sold to consumers without appropriate labelling and instructions for use. __________________ 13 Council Joint Action 97/396/JHA of 16 June 1997 concerning the information exchange, risk assessment and control of new synthetic drugs (OJ L 167, 25.6.1997, p. 1). 14 Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk assessment and control of new psychoactive substances (OJ L 127, 20.5.2005, p. 32).
Amendment 33 #
Proposal for a regulation
Article 1 – paragraph 1 – point 3
Article 1 – paragraph 1 – point 3
Regulation (EC) No 1920/2006
Article 5a – paragraph 1
Article 5a – paragraph 1
Amendment 36 #
Proposal for a regulation
Article 1 – paragraph 1 – point 3
Article 1 – paragraph 1 – point 3
Regulation (EC) No 1920/2006
Article 5b – paragraph 2 – point a
Article 5b – paragraph 2 – point a
(a) a first indication of the nature or scale of health and social risks associated with the new psychoactive substance, including contraindications for use with other substances when available;